Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)This is a prospective, multicenter, randomized, double-blinded, placebo-controlled Phase 3 study of a microbiota suspension of intestinal microbes.Recruiting Principal Investigator Theodore SteinerBody Locations and Systems Clostridium Difficile InfectionsArea VancouverAge 18 and above
SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection (ECOSPORIII)The purpose of this study is to demonstrate the superiority of SER-109 vs placebo to reduce recurrence of CDI in adults up to 8 weeks after initiation of treatment. Recruiting Principal Investigator Theodore SteinerBody Locations and Systems Clostridium Difficile Infections, Clostridium Difficile InfectionsArea VancouverAge 18 and above
ECOSPOR IV: An Open-Label Extension of Study SERES 012 Evaluating SER-109 in Subjects With Recurrent Clostridium Difficile Infection The purpose of this study is to assess safety and efficacy of SER-109 in reducing recurrence of Clostridium difficile infection (CDI) in adults who had a CDI recurrence within 8 weeks after receipt of SER-109 or Placebo in Study SERES-012. Recruiting Principal Investigator Theodore SteinerBody Locations and Systems Clostridium Difficile Infections, Clostridium Difficile InfectionsArea VancouverAge 18 and above
Probiotics: Prevention of Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT): A Feasibility Clinical Trial (PROSPECT)Probiotics are commercially available live bacteria thought to have health benefits when ingested.Closed for Recruitment Principal Investigator Peter DodekBody Locations and Systems Pneumonia, Clostridium Difficile InfectionsArea VancouverAge 18 and above
Study of a Candidate Clostridium Difficile Toxoid Vaccine (Cdiffense) in Subjects at Risk for C. Difficile InfectionThe aim of this study is to evaluate the efficacy of the candidate Clostridium difficile (C. difficile) vaccine to prevent primary symptomatic C. difficile infection (CDI) in subjects a risk for CDI where there is a substantial unmet medical need. Closed for Recruitment Principal Investigator Theodore SteinerBody Locations and Systems Clostridium Difficile InfectionsArea VancouverAge 50 and above
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD2)This is the first prospective, multi-center, double-blinded, randomized controlled study of a microbiota suspension derived from intestinal microbes. Patients who have had at least two recurrences of C.Closed for Recruitment Principal Investigator Theodore SteinerBody Locations and Systems Clostridium Difficile InfectionsArea VancouverAge 18 and above
A Prospective Trial of Frozen-and-Thawed Fecal Microbiota Transplantation for Recurrent Clostridium Difficile InfectionThe primary goal of this proposal is to study the outcome of patients with recurrent Clostridium Difficile Infection (CDI) treated with frozen Fecal Microbiota Transplantation (FMT) in an open-labelled controlled trial.Closed for Recruitment Principal Investigator Theodore SteinerBody Locations and Systems Clostridium Difficile InfectionsArea VancouverAge 18 and above
Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated DiarrheaThis clinical study is conducted to assess the efficacy of cadazolid compared to vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD). Closed for Recruitment Principal Investigator Theodore SteinerBody Locations and Systems Clostridium Difficile InfectionsArea VancouverAge 18 and above
Clostridium Difficile Vaccine Efficacy Trial (Clover)The Clover trial is evaluating an investigational vaccine that may help to prevent Clostridium difficile infection. Participants in the study are adults 50 years of age and older, who are at risk of developing Clostridium difficile infection.Closed for Recruitment Principal Investigator Titus WongBody Locations and Systems Clostridium Difficile Infections, Clostridium Difficile InfectionsArea VancouverAge 50 and above
